Exploring the role of antibiotics and steroids in managing respiratory diseases
© 2022 Wiley Periodicals LLC..
Respiratory diseases (RDs), such as chronic obstructive pulmonary disease, cystic fibrosis, asthma, and pneumonia, are associated with significant morbidity and mortality. Treatment usually consists of antibiotics and steroids. Relevant published literature reviews, studies, and clinical trials were accessed from institutional and electronic databases. The keywords used were respiratory diseases, steroids, antibiotics, and combination of steroids and antibiotics. Selected articles and literature were carefully reviewed. Antibiotics are often prescribed as the standard therapy to manage RDs. Types of causative respiratory pathogens, spectrum of antibiotics activity, route of administration, and course of therapy determine the type of antibiotics that are prescribed. Despite being associated with good clinical outcome, treatment failure and recurrence rate are still high. In addition, antibiotic resistance has been widely reported due to bacterial mutations in response to the use of antibiotics, which render them ineffective. Nevertheless, there has been a growing demand for corticosteroids (CS) and antibiotics to treat a wide variety of diseases, including various airway diseases, due to their immunosuppressive and anti-inflammatory properties. The use of CS is well established and there are different formulations based on the diseases, such as topical administration, tablets, intravenous injections, and inhaled preparations. Both antibiotics and CS possess similar properties in terms of their anti-inflammatory effects, especially regulating cytokine release. Thus, the current review examines and discusses the different applications of antibiotics, CS, and their combination in managing various RDs. Drawbacks of these interventions are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of biochemical and molecular toxicology - 36(2022), 10 vom: 01. Okt., Seite e23174 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chellappan, Dinesh K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 13.10.2022 Date Revised 13.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jbt.23174 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34381692X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34381692X | ||
| 003 | DE-627 | ||
| 005 | 20231226021331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jbt.23174 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM34381692X | ||
| 035 | |a (NLM)35861662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chellappan, Dinesh K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the role of antibiotics and steroids in managing respiratory diseases |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2022 | ||
| 500 | |a Date Revised 13.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Respiratory diseases (RDs), such as chronic obstructive pulmonary disease, cystic fibrosis, asthma, and pneumonia, are associated with significant morbidity and mortality. Treatment usually consists of antibiotics and steroids. Relevant published literature reviews, studies, and clinical trials were accessed from institutional and electronic databases. The keywords used were respiratory diseases, steroids, antibiotics, and combination of steroids and antibiotics. Selected articles and literature were carefully reviewed. Antibiotics are often prescribed as the standard therapy to manage RDs. Types of causative respiratory pathogens, spectrum of antibiotics activity, route of administration, and course of therapy determine the type of antibiotics that are prescribed. Despite being associated with good clinical outcome, treatment failure and recurrence rate are still high. In addition, antibiotic resistance has been widely reported due to bacterial mutations in response to the use of antibiotics, which render them ineffective. Nevertheless, there has been a growing demand for corticosteroids (CS) and antibiotics to treat a wide variety of diseases, including various airway diseases, due to their immunosuppressive and anti-inflammatory properties. The use of CS is well established and there are different formulations based on the diseases, such as topical administration, tablets, intravenous injections, and inhaled preparations. Both antibiotics and CS possess similar properties in terms of their anti-inflammatory effects, especially regulating cytokine release. Thus, the current review examines and discusses the different applications of antibiotics, CS, and their combination in managing various RDs. Drawbacks of these interventions are also discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antibiotics | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a drawbacks | |
| 650 | 4 | |a interactions | |
| 650 | 4 | |a respiratory diseases | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Prasher, Parteek |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Shakti D |e verfasserin |4 aut | |
| 700 | 1 | |a Yee, Tong W |e verfasserin |4 aut | |
| 700 | 1 | |a Kah, Tiong K |e verfasserin |4 aut | |
| 700 | 1 | |a Xyan, Toh W |e verfasserin |4 aut | |
| 700 | 1 | |a Kid, Tang W |e verfasserin |4 aut | |
| 700 | 1 | |a Si, Teoh H |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Ting S |e verfasserin |4 aut | |
| 700 | 1 | |a Molugulu, Nagashekhara |e verfasserin |4 aut | |
| 700 | 1 | |a Sakthivel, Lakshmana P |e verfasserin |4 aut | |
| 700 | 1 | |a Chellian, Jestin |e verfasserin |4 aut | |
| 700 | 1 | |a Madheswaran, Thiagarajan |e verfasserin |4 aut | |
| 700 | 1 | |a Malipeddi, Himaja |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Yogendra |e verfasserin |4 aut | |
| 700 | 1 | |a Dureja, Harish |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Deepak N |e verfasserin |4 aut | |
| 700 | 1 | |a Negi, Poonam |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Thangavelu, Lakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Piyush K |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Niraj K |e verfasserin |4 aut | |
| 700 | 1 | |a Shastri, Madhur D |e verfasserin |4 aut | |
| 700 | 1 | |a MacLoughlin, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sachin K |e verfasserin |4 aut | |
| 700 | 1 | |a Gulati, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biochemical and molecular toxicology |d 1998 |g 36(2022), 10 vom: 01. Okt., Seite e23174 |w (DE-627)NLM093581521 |x 1099-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:10 |g day:01 |g month:10 |g pages:e23174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jbt.23174 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 10 |b 01 |c 10 |h e23174 | ||